Table 4.
Safety of TACE+apatinib versus TACE in adverse effect, which was analyzed by classification of TACE agents.
| Outcome | Subgroups | Included RCTs | OR(95%CI) from pairwise meta-analysis | p, I2 | Publication bias | Grade |
|---|---|---|---|---|---|---|
| Hypertension | Adriamycin+platinum+fluorouracil | 5 | 25.007 (5.186, 120.575)* | 0.002, 76.9%# | 0.327, 0.044¶ | Low |
| Adriamycin+platinum | 10 | 16.078( 5.551, 46.566)* | 0.000, 81.5%# | 0.074, 0.015¶ | Low | |
| Hand-foot syndrome | Adriamycin+platinum+fluorouracil | 6 | 14.349 (2.271, 90.649)* | 0.004, 71.0%# | 0.851, 0.216 | Moderate |
| Adriamycin+platinum | 9 | 12.496 (3.123, 50.004)* | 0.000, 85.0%# | 0.037, 0.000¶ | Low | |
| Fatigue | Adriamycin+platinum+fluorouracil | 4 | 1.686( 0.711, 3.995) | 0.028, 63.1% | 0.050, 0.004¶ | Moderate |
| Adriamycin+platinum | 5 | 1.194 (0.735, 1.939) | 0.897, 0.0% | 0.174, 0.332 | High | |
| Fever | Adriamycin+platinum+fluorouracil | 4 | 1.138 (0.690, 1.875) | 0.479, 0.0% | 0.34, 0.646 | High |
| Adriamycin+platinum | 9 | 1.086 (0.805, 1.464) | 0.997, 0.0% | 0.029, 0.023¶ | Moderate | |
| Nausea–vomiting | Adriamycin+platinum+fluorouracil | 6 | 1.445 (0.845, 2.472) | 0.954, 0.0% | 0.190, 0.756 | High |
| Adriamycin+platinum | 10 | 1.050 (0.711, 1.550) | 0.170, 29.9% | 0.655, 0.586 | High | |
| Diarrhea | Adriamycin+platinum+fluorouracil | 7 | 2.331 (1.194, 4.553)* | 0.328, 13.4% | 0.099, 0.072 | High |
| Adriamycin+platinum | 10 | 1.781 (0.859, 3.695) | 0.001, 66.6%# | 0.655, 0.117 | Moderate |
*Significant differences #Substantial heterogeneity ¶Publication bias.